Immunological Consequences of JAK Inhibition: Friend

Current Hematologic Malignancy Reports
10, 370-379
DOI: 10.1007/s11899-015-0284-z

Citation Report

#	Article	IF	Citations
1	Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. Case Reports in Hematology, 2016, 2016, 1-4.	0.3	17
2	The <scp>JAK</scp>/<scp>STAT</scp> pathway in obesity and diabetes. FEBS Journal, 2016, 283, 3002-3015.	2.2	184
4	JAK2 inhibitors. Medicina ClÃnica (English Edition), 2016, 147, 70-75.	0.1	0
5	Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene. Medical Oncology, 2017, 34, 31.	1.2	1
6	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Review of Hematology, 2017, 10, 617-625.	1.0	29
7	Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Molecular and Cellular Endocrinology, 2017, 451, 1-14.	1.6	228
8	Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathogens, 2017, 13, e1006740.	2.1	71
9	Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature. Infectious Diseases, 2018, 50, 381-387.	1.4	40
10	JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. Human Pathology, 2018, 73, 171-175.	1.1	10
11	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. Future Oncology, 2018, 14, 137-150.	1.1	11
12	Ruxolitinibâ€associated infections: A systematic review and metaâ€analysis. American Journal of Hematology, 2018, 93, 339-347.	2.0	164
13	Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of aÂrare case and review of literature. Memo - Magazine of European Medical Oncology, 2018, 11, 348-350.	0.3	3
14	Ruxolitinib for the Treatment of Essential Thrombocythemia. HemaSphere, 2018, 2, e56.	1.2	11
15	Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. American Journal of Hematology, 2019, 94, 319-326.	2.0	59
16	Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?. BioMed Research International, 2018, 2018, 1-9.	0.9	33
17	The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 117-127.	1.2	204
18	Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. Annals of Hematology, 2019, 98, 215-218.	0.8	19
19	JAKâ€“STAT inhibition impairs Kâ€RASâ€driven lung adenocarcinoma progression. International Journal of Cancer, 2019, 145, 3376-3388.	2.3	54

#	Article	IF	Citations
20	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	1.1	6
21	Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors. Current Fungal Infection Reports, 2019, 13, 86-98.	0.9	34
22	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. Journal of Immunology, 2019, 203, 2100-2109.	0.4	16
23	A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib. BMC Infectious Diseases, 2019, 19, 287.	1.3	19
24	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Frontiers in Oncology, 2019, 9, 1186.	1.3	142
25	Toxoplasmosis and secondary Guillainâ€BarrÃ© associated with ruxolitinib as graftâ€versusâ€host disease treatment. Pediatric Blood and Cancer, 2019, 66, e27446.	0.8	6
26	Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib. Bone Marrow Transplantation, 2019, 54, 762-764.	1.3	0
27	Myeloproliferative and lymphoproliferative disorders: State of the art. Hematological Oncology, 2020, 38, 121-128.	0.8	16
28	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives. HemaSphere, 2020, 4, e424.	1.2	49
29	Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins. Cells, 2020, 9, 2297.	1.8	61
30	Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Cancers, 2020, 12, 3132.	1.7	18
31	Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. Saudi Pharmaceutical Journal, 2020, 28, 1101-1111.	1.2	16
32	JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis. International Immunopharmacology, 2020, 86, 106731.	1.7	14
33	Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma. BioMed Research International, 2020, 2020, 1-17.	0.9	38
34	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews, 2020, 33, .	5.7	68
35	Impaired virusâ€specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematological Oncology, 2020, 38, 554-559.	0.8	4
36	Targeted Therapies: Friends or Foes for Patientâ€™s NK Cell-Mediated Tumor Immune-Surveillance?. Cancers, 2020, 12, 774.	1.7	10
37	Finally, a Successful Randomized Trial for GVHD. New England Journal of Medicine, 2020, 382, 1853-1854.	13.9	8

#	Article	IF	Citations
38	Glycosides of Caulis Lonicerae inhibits the inflammatory proliferation of <scp>IL</scp>â€1Î²â€mediated fibroblastâ€like synovial cells cocultured with lymphocytes. Phytotherapy Research, 2021, 35, 2807-2823.	2.8	2
39	COVID-19: High-JAKing of the Inflammatory â€œFlightâ€•by Ruxolitinib to Avoid the Cytokine Storm. Frontiers in Oncology, 2020, 10, 599502.	1.3	9
40	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances, 2021, 5, 913-925.	2.5	11
41	Evidence of robust memory Tâ€cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2). British Journal of Haematology, 2021, 193, 692-696.	1.2	13
42	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. Food and Chemical Toxicology, 2021, 150, 112087.	1.8	17
44	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021, 35, 3573-3577.	3.3	41
45	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitorsâ€”A Strategy for Hematological Malignancies?. Cancers, 2021, 13, 2611.	1.7	15
46	NK Cells in Myeloproliferative Neoplasms (MPN). Cancers, 2021, 13, 4400.	1.7	0
47	Impaired response to first <scp>SARSâ€CoV</scp>â€2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. American Journal of Hematology, 2021, 96, E408-E410.	2.0	30
48	Current and future status of JAK inhibitors. Lancet, The, 2021, 398, 803-816.	6.3	117
49	Efficacy and safety of ruxolitinib in ineffective erythropoiesis suppression as a pretransplantation treatment for pediatric patients with betaâ€thalassemia major. Pediatric Blood and Cancer, 2021, 68, e29338.	0.8	1
51	Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review. Internal Medicine, 2022, 61, 1271-1278.	0.3	3
52	The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinib. Meditsinskiy Sovet, 2020, , 83-94.	0.1	1
53	The immune landscape in BCRâ€ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy. British Journal of Haematology, 2022, 196, 1149-1158.	1.2	11
54	The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines, 2021, 9, 1480.	1.4	17
55	Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes. Biomedicines, 2021, 9, 1413.	1.4	1
56	Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence. Biochemical Pharmacology, 2021, 194, 114816.	2.0	2
57	New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. Medicina (Lithuania), 2021, 57, 1181.	0.8	0

#	Article	IF	Citations
58	Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors. Frontiers in Immunology, 2021, 12, 750346.	2.2	6
59	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies. Journal of Fungi (Basel, Switzerland), 2021, 7, 1058.	1.5	21
60	Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib. Frontiers in Medicine, 2022, 9, 826537.	1.2	5
64	Hepatitis B reactivation during ruxolitinib treatment. Annals of Hematology, 2022, , 1.	0.8	5
65	Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression. Frontiers in Immunology, 2022, 13, .	2.2	0
66	Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis. Therapie, 2022, 77, 649-656.	0.6	6
67	ÐœÑ–Ñ”Ð»Ð¾Ð¿Ñ€Ð¾Ñ–Ñ„ÐµÑ€Ð°Ñ‚Ð¸Ð²Ð½Ñ– Ñ‚Ð° Ð»Ñ–Ð¼Ñ„Ð¾Ð¿Ñ€Ð¾Ð»Ñ–Ñ„ÐµÑ€Ð°Ñ‚Ð¸Ð²Ð½Ñ–	0.1	Ð·Ð°Ñ.ΩÐ²Ð¾Ñ€
68	Curcumin inhibits the cancerâ€‘associated fibroblastâ€‘derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway. International Journal of Oncology, 2022, 61, .	1.4	27
69	Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 1642-1648.	1.3	16
70	The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Frontiers in Immunology, 0, 13, .	2.2	11
71	The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	3
72	Infections in primary immunodeficiency. , 2022, , 747-790.		0
73	Tyrosine-Kinase Inhibitors. , 2022, , 273-292.		0
74	Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma. Clinical Infection in Practice, 2023, 17, 100214.	0.2	3
75	Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. Journal of Clinical Medicine, 2023, 12, 578.	1.0	8
76	Therapeutic effects of Panax notoginseng saponins in rheumatoid arthritis: network pharmacology and experimental validation. Bioengineered, 2022, 13, 14438-14449.	1.4	3
77	Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature. Expert Opinion on Drug Safety, 2023, 22, 469-476.	1.0	0
78	What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?. Leukemia, 2023, 37, 1186-1190.	3.3	2

#	Article	IF	Citations